Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 15.15

Immunosuppression Use for Maintenance by Regimen

Two Years Following Transplantation, 1998 to 2006

Recipients with Heart-Lung Transplants

  Transplant Year
1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 47 51 48 27 33 29 40 35 31
Functioning Graft at 2 Years PostTx 20 22 26 18 18 12 29 24 16
With Maintenance Use Recorded at 2 Years PostTx 20 22 24 16 18 12 28 23 14
Tac 0.0% 0.0% 4.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA 0.0% 0.0% 4.2% 6.3% 0.0% 8.3% 0.0% 4.3% 0.0%
--- + OtherAntimet 0.0% 0.0% 4.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.3% 0.0%
CyA + Steroids 5.0% 9.1% 8.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + Steroids 0.0% 0.0% 4.2% 25.0% 11.1% 0.0% 7.1% 13.0% 21.4%
CyA + MMF/MPA + Steroids 25.0% 9.1% 16.7% 6.3% 16.7% 8.3% 10.7% 8.7% 0.0%
Tac + MMF/MPA + Steroids 40.0% 31.8% 16.7% 37.5% 16.7% 41.7% 39.3% 39.1% 57.1%
--- + OtherAntimet + Steroids 0.0% 0.0% 0.0% 0.0% 5.6% 0.0% 3.6% 0.0% 0.0%
CyA + OtherAntimet + Steroids 20.0% 22.7% 8.3% 0.0% 11.1% 16.7% 7.1% 8.7% 0.0%
Tac + OtherAntimet + Steroids 10.0% 13.6% 20.8% 12.5% 16.7% 25.0% 21.4% 13.0% 14.3%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 5.6% 0.0% 0.0% 0.0% 0.0%
Tac + Siro/Evero + Steroids 0.0% 9.1% 4.2% 12.5% 16.7% 0.0% 7.1% 4.3% 0.0%
Other Regimen 0.0% 4.5% 8.3% 0.0% 0.0% 0.0% 3.6% 4.3% 7.1%


Source: OPTN/SRTR Data as of May 4, 2009.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.



PDF FormatRequires Adobe Acrobat Reader